VOTRIENT

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug VOTRIENT contains one active pharmaceutical ingredient (API):

1 Pazopanib
UNII 33Y9ANM545 - PAZOPANIB HYDROCHLORIDE

Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.

Read about Pazopanib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
VOTRIENT Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01EX03 Pazopanib L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10041L, 10042M, 10043N, 10047T, 10052C, 10054E, 11252F, 11261Q, 2029T, 2030W, 2201W, 2232L
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 526517050089517, 526517050089617, 526517050089717
Country: CA Health Products and Food Branch Identifier(s): 02352303
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 2776-MEE-0517
Country: EE Ravimiamet Identifier(s): 1482027, 1482038, 1482049, 1482050
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 10628001, 10628004
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 058261, 085366
Country: FR Base de données publique des médicaments Identifier(s): 62894653, 63803884
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 174621, 174624
Country: HK Department of Health Drug Office Identifier(s): 60351, 60352, 62096, 62097
Country: IE Health Products Regulatory Authority Identifier(s): 88558, 88559
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 6703, 6705
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291028F1023
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1055472, 1055473, 1055474, 1055475
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 174M2011
Country: NL Z-Index G-Standaard, PRK Identifier(s): 95265, 95273
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 13984, 13985
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100222878, 100222884
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64502001, W64502002, W64503001, W64503002
Country: SG Health Sciences Authority Identifier(s): 14022P, 14023P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 1243091, 1243092
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699504092134, 8699504092141, 8699504092158, 8699504092165
Country: US FDA, National Drug Code Identifier(s): 0078-0670
Country: ZA Health Products Regulatory Authority Identifier(s): 44/26/0348, 44/26/0349

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.